{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-096928","form_type":"8-K","ticker":"CLRB","cik":"0001279704","company_name":"Cellectar Biosciences, Inc.","filed_at":"2025-10-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.019281+00:00","generated_at":"2026-05-17T04:33:05.947048+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"EMA confirms iopofosine I 131 eligible for Conditional Marketing Authorization in post-BTKi WM","bullets":["SAWP advised filing a CMA for iopofosine I 131 in post-BTKi refractory WM could be acceptable.","CMA submission planned for early 2026; potential commercial launch in up to 30 EMA countries by 2027.","CLOVER WaM Phase 2 study showed ORR 83.6%, MRR 58.2%; >70% patients were post-BTKi.","Company also pursuing US NDA under accelerated approval, contingent on funding for confirmatory study.","Estimated 35,000-45,000 WM patients in Europe with significant unmet need."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-096928","json":"https://secwatch.observer/filing/0001104659-25-096928.json","markdown":"https://secwatch.observer/filing/0001104659-25-096928.md","text":"https://secwatch.observer/filing/0001104659-25-096928.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1279704/000110465925096928/0001104659-25-096928-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1279704/000110465925096928/tm2528016d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T04:33:05.947048+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}